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Background: The present study was conducted to investigate the possible outcome of interaction between
endothelial nitric oxide (NOS3) G894T and cholesteryl ester transfer TaqIB variants on the risk of coronary artery
disease (CAD) and type 2 diabetes mellitus (T2DM). The sample included a total of 207 CAD patients (102 CAD
patients with T2DM and 105 CAD patients without T2DM). There were also 101 patients with T2DM and 92
age- and sex-matched healthy individuals as controls. All study participants were from Western Iran. The sample
was genotyped by polymerase chain reaction-restriction fragment length polymorphism.
Results: The presence of NOS3 T allele was not associated with the risk of CAD or T2DM, and the CETP B1 allele
was only significantly associated with the increased risk of CAD in total CAD patients (odds ratio (OR) = 5.1,
p= 0.019). However, the concomitant presence of both CETP B1 and NOS3 T alleles significantly increased the risk
of CAD in total CAD patients (OR = 18.1, p< 0.001), in CAD patients without T2DM (OR= 27.1, p= 0.03), and in CAD
patients with T2DM (OR= 13.5, p= 0.002). Also, the presence of both alleles increased the risk of T2DM (OR= 12,
p= 0.004).
Conclusions: Our findings, for the first time, indicate that NOS3 T allele strongly interacts with CETP B1 allele to
augment the risk of CAD and T2DM in the population of Western Iran.
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Cholesteryl ester transfer protein (CETP) participates in
reverse cholesterol transport by transfering cholesteryl
esters from high-density lipoprotein-cholesterol (HDL-
C) to apolipoprotein-B containing particles in exchange
for triglycerides (TG), thereby reducing the concentra-
tion of HDL-C [1-3].* Correspondence: zrahimi@kums.ac.ir
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reproduction in any medium, provided the orCETP gene located on chromosome 16q21 consists of
16 exons and 15 introns and has several genetic poly-
morphisms affecting CETP activity among which TaqIB
polymorphism has been most widely studied. This poly-
morphism results from G to A base pair change at nu-
cleotide 277 in intron 1 of the CETP gene which
disrupts TaqI restriction site (single-nucleotide poly-
morphism (SNP) rs708272). The allele containing the
TaqI endonuclease site is called B1, while the allele with-
out the restriction site is called B2. The less common B2
allele has been associated with increased HDL-C levels
and decreased CETP activity and levels [4,5]. The associ-
ation of CETP variants with coronary artery disease
(CAD) and type 2 diabetes mellitus (T2DM) has beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[1,6-9].
Nitric oxide synthase (NOS) synthesizes NO through
the oxidation of L-arginine to L-citrulline which is an
important regulator of vasodilator tone and blood pres-
sure [10,11]. One of the most clinically important poly-
morphisms of NOS3, the G894T polymorphism, results
from G to T conversion at nucleotide 894 of exon 7 of
gene that changes Glu298Asp (SNP rs1799983). The
presence of this polymorphism reduces the NO produc-
tion. There are several studies reporting controversial
results related to the role of NOS3 variants on the sus-
ceptibility to CAD and T2DM [12-17].
Recently, we reported that the B1 allele of CETP
increased the risk of CAD and T2DM 1.65- and 1.7-fold,
respectively [18]. Also, we indicated that the risk of
CAD was increased by 2.15-fold in the presence of T al-
lele of NOS3 in our population [19]. To our knowledge,
there is no report related to the influence of concomi-
tant presence of CETP variants and NOS3 G894T poly-
morphism on the risk of CAD and T2DM in the
literature.
The aim of the present study was to examine the inter-
action between CETP TaqIB and NOS3 G894T variants
and its effect on the risk of CAD and T2DM in the
population of Western Iran.
Materials and methods
The sample consisted of 308 patients and 92 controls.
There were 207 total CAD patients including 113 males
and 94 females with the mean age of 56.9 ± 8.6 years
from whom there were 102 CAD patients with T2DM
(CAD/T2DM) and 105 CAD patients without T2DM.
There were 101 patients with T2DM including 51 males
and 50 females with the mean age of 56.5 ± 9.8 years.
The controls were 92 non-diabetic individuals that con-
sisted of 47 males and 45 females with the mean age of
54.3 ± 8.5 years who were evaluated by angiography for
suspected CAD but had normal coronary arteries. All
patients and controls were recruited from Imam Ali
Hospital of Kermanshah University of Medical Sciences
and were from Western Iran with Kurdish ethnic
background.
Patients were referred to the Cardiology Division of
the Imam Ali Hospital of the Kermanshah University of
Medical Sciences to undergo their first coronary angiog-
raphy to evaluate the presence and extent of CAD. Cor-
onary artery involvement was defined as a ≥50%
diameter obstruction of a major coronary vessel. The
diagnosis of diabetes in patients was confirmed using
WHO criteria [20]. Written informed consent was
obtained from each individual before participation in the
study. The study was approved by the Ethics Committee
of Kermanshah University of Medical Sciences and wasin accordance with the principles of the Declaration of
Helsinki (2000).
Genotype analysis
DNA was extracted from the leukocytes of the whole
blood by the phenol-chloroform method as previously
described in [21]. The NOS3 G894T polymorphism was
detected by amplification of a region in exon 7 of the
gene using the forward primer of 50-AAG GCA GGA
GAC AGT GGA TGG A-30 and the reverse primer of
50-CCC AGT CAA TCC CTT TGG TGC TCA-30 and
subsequent digestion with MboI restriction enzyme as
previously described in [22].
For the detection of the CETP TaqIB genotypes, the
following primers were used: 50-CACTAGCCCAGAGA
GAGGAGTGCC-30 and 50 CTGAGCCCAGCCGCACA
CTAAC-30 to amplify the 535-bp fragment in intron 1
of the CETP gene which was amplified by PCR, and
the products were digested with TaqIB restriction
endonuclease as previously described in [18].
Chemical analysis
Plasma total cholesterol (TC) and TG were measured by
the standard enzymatic method (Pars Azmoon kit, Pars
Azmoon Inc., Tehran, Iran), using an automated Techni-
con RA-1000 (Technicon Instruments Corporation, NY,
USA). The plasma low-density lipoprotein-cholesterol
(LDL-C) and HDL-C levels were measured using com-
mercially available enzyme assay kits (Pars Azmoon kit,
Iran).
Statistical analysis
The allelic frequencies were calculated by the chromo-
some counting method. The genotype and allele fre-
quencies of CETP and NOS3 in CAD and T2DM
patients were compared to controls, and the significance
of differences calculated using χ2 test. Odds ratios (OR)
were calculated as estimates of relative risk for disease
and 95% confidence intervals (CI) obtained by SPSS lo-
gistic regression software. A two-tailed Student's t test
was used to compare quantitative data. Statistical signifi-
cance was assumed at the p < 0.05 level. The SPSS statis-
tical software package version 16 was used for the
statistical analysis.
Results
The biochemical characteristics of patients and controls
are presented in Table 1. The plasma level of LDL-C and
TG was significantly higher, and HDL-C level was sig-
nificantly lower in both CAD and T2DM patients com-
pared to controls. In Table 2, the lipid profile of CAD/
T2DM patients has been compared to CAD, T2DM, and
controls. Significantly higher level of TG and lower level
of HDL-C were observed in CAD/T2DM patients
Table 1 Demographic and biochemical parameters of the controls and patients
Parameters CAD patients with and without
diabetes (n=207)
T2DM (n=101) Control subjects
(n=92)
Age (years) 56.9 ± 8.6*NS 56.5 ± 9.8 54.3 ± 8.5
Sex (M/F) 113/94*NS 51/50 47/45
FBS (mg/dl) 136.2 ± 59.6, p< 0.001 162.9 ± 71.3, p< 0.001 97.0 ± 20.1
History of hypertension (%) 102 (49.6), p< 0.001 29 (28.7), p= 0.68 24 (26.1)
LDL-C (mg/dl) 96 ± 28, p< 0.001 98.5 ± 38.4, p< 0.001 83 ± 18
HDL-C(mg/dl) 47 ± 9.3, p= 0.007 45.2 ± 10.2, p< 0.001 49.8 ± 5.8
TC (mg/dl) 186 ± 42, p= 0.046 185.9 ± 45.8, p= 0.09 177± 26
TG (mg/dl) 177 ± 89, p= 0.038 200.8 ± 99.3, p= 0.001 156± 48
BMI (kg/m2) 26 ± 2.7*NS 26.2 ± 2.7*NS 26.6 ± 3.7
Plasma fasting blood sugar (FBS), LDL-C, HDL-C, TC, and TG levels, as well as age and BMI were compared between patients and controls using two-tailed
Student’s t test. The sex was compared between two groups by the χ2-test. NS, not significant; *p> 0.05.
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though the level of LDL-C was higher in CAD/T2DM
patients compared to those in CAD and control groups,
the differences reached statistically significant values
only with controls. Plasma total cholesterol was insignifi-
cantly increased in CAD/T2DM group compared to
those in all studied groups. The same results were
obtained when the levels of TG, HDL-C, and LDL-C
were compared between T2DM patients with CAD and
controls. In CAD patients, the level of LDL-C was sig-
nificantly increased when compared to that in controls
(Table 2). The plasma lipid and lipoprotein profiles cate-
gorized based on gender in each group are shown in
Table 2. Comparison of genders in each group for lipid
and lipoprotein levels indicated that women with T2DM
had significantly higher plasma total cholesterol than
males with T2DM (Table 2). Table 3 indicates the syner-
gistic effect of both CETP B1 and NOS3 T alleles on the
risk of CAD and T2DM. The concomitant presence ofTable 2 Comparison of plasma lipid and lipoprotein levels in
Patients (n) TG (mg/dl) TC (mg
CAD with T2DM 202.2 ± 87.9* 207.6 ±
Males (52) 206.4 ± 85.9 225.8 ±
Females (50) 197.8 ± 90.6 188.6 ±
CAD without T2DM 151.8 ± 83.2*** 182.8 ±
Males (61) 150.3 ± 93.3 184.2 ±
Females (44) 153.9 ± 67.5 180.8 ±
T2DM 200.8 ± 99.3* 185.9 ±
Males (51) 198.4 ± 110.6 175.9 ±
Females (50) 203.2 ± 87.1 196.2 ±
Controls 161.5 ± 64.5 176.8 ±
Males (47) 161.1 ± 53.5 179.7 ±
Females (45) 161.8 ± 74.8 173.7 ±
*p< 0.05 compared to CAD without T2DM and controls; **p< 0.05 compared to con
compared between males and females in each group.both alleles increased the risk of CAD significantly by
27.1-, 18.1-, and 13.5-fold in CAD patients without
T2DM, total CAD, and CAD patients with T2DM, re-
spectively. Also, the presence of both alleles (B1 and T)
increased the risk of T2DM by 12-fold (p= 0.004)
(Table 3). However, as demonstrated in Table 3, the
presence of NOS3 T allele alone did not increase the risk
of CAD or T2DM. Further, the presence of CETP B1 al-
lele was significantly (p= 0.019) associated with 5.1-fold
increased risk of CAD in total CAD patients.
Discussion
Diabetes mellitus is a strong risk factor for the develop-
ment of atherosclerosis [6] that is related to dyslipidemia
linked to insulin resistance characterized by a high tri-
glyceride level, a high LDL-C, and a low HDL-C level
[23]. In fact, decreased concentrations of HDL-C have
been reported to be significantly related to CAD in
patients with type 2 diabetes mellitus [7]. The significantpatients and controls
/dl) LDL-C (mg/dl) HDL-C (mg/dl)
185.4 97.8 ± 30.8** 44.7 ± 10.5*
253.6 98.6 ± 25.9 43.8 ± 8.2
56.2 96.8 ± 35.3 45.6 ± 12.5
36.1 94.1 ± 25.9** 49.2 ± 7.5***
37.7 97.2 ± 27.6 48.2 ± 8.2
34.1 89.8 ± 23.1 50.4 ± 6.1
45.8 98.5 ± 38.4** 45.2 ± 10.2*
41.2**** 90.9 ± 31.3* 42.5 ± 9.7*
48.3 106.2 ± 43.3 47.9 ± 10.1
25.8 82.8 ± 17.8 49.8 ± 5.8
27.2 85.3 ± 17.4 48.4 ± 5*
24.2 80 ± 17.9 51.3 ± 6.1
trols; ***p< 0.05 compared to CAD with T2DM and T2DM; ****p< 0.05
Table 3 The carrier odds ratio interaction between CETP B1 and NOS3 894 T alleles
CETP B1 NOS3 T Total CAD patients n (%)
ORs (95% CI) n=207
CAD with T2DM n (%)
ORs (95% CI) n=102
CAD without T2DM n (%)
ORs (95% CI) n=105
T2DM patients n (%)
ORs (95% CI) n=101
Controls
n (%) n=92
− − 3 (1.4) 2 (2) 1 (1) 2 (2) 8 (8.7)
− + 3 (1.4) 3 (2.9) 0 2 (2) 12 (13)
0.67 (0.11–4.17, p= 0.67) 1 (0.14–7.4, p= 1) 0.67 (0.1–5.7, p= 0.71)
+ − 113 (54.6) 53 (52) 60 (57.1) 58 (57.4) 59 (64.2)
5.1 (1.3–20, p= 0.019) 3.6 (0.73–17.7, p= 0.11) 8.14 (1–67, p= 0.05) 3.9 (0.8–19.3, p= 0.09)
+ + 88 (42.6) 44 (43.1) 44 (41.9) 39 (38.6) 13 (14.1)
18.1 (4.2–76.8, p< 0.001) 13.5 (2.6–71.8, p= 0.002) 27.1 (3.1–237, p= 0.003) 12 (2.25–63.8, p= 0.004)
Interaction with respect to B2 or G alleles in CAD and T2DM patients compared with controls. Overall distribution of interaction between CETP B1 and NOS3 T
alleles in total CAD compared to controls (χ2 = 42.4, df = 3, p< 0.001) and between CAD with T2DM compared to controls (χ2 = 25.7, df = 3, p< 0.001), as well as
comparison between CAD without T2DM and controls (χ2 = 33.6, df = 3, p< 0.001). Overall distribution of interaction between CETP B1 and NOS3 T alleles in T2DM
patients compared to controls (χ2 = 23.4, df = 3, p< 0.001).
Rahimi et al. Human Genomics 2012, 6:20 Page 4 of 5
http://www.humgenomics.com/content/6/1/20higher level of TG and lower level of HDL-C observed
in CAD patients with T2DM compared to those in CAD
patients without diabetes in the present study confirm
the role of dyslipidemia for predicting the risk of CAD
in T2DM patients.
Both genetics and environmental factors have import-
ant roles in the pathogenesis of CAD and T2DM [24].
The role of genetic factors appears to be considerably
different between various populations [25].
The most commonly studied polymorphism of CETP
is TaqIB with a frequency of 0.44 in Caucasian popula-
tions and is associated with decreased CETP mass, an
increase in HDL-cholesterol, and modulating the risk for
diabetic complications in patients with T2DM. The pres-
ence of homozygous B1 allele is associated with lowest
while in B2B2 carriers there is highest HDL-cholesterol
concentration [5,26]. The role of CETP TaqIB poly-
morphism on the risk of CAD and T2DM either through
its influence on lipid metabolism or independent of its
effect on lipid profile has been reported in various popu-
lations [1,6-9]. Previously, we reported an association be-
tween the B1 allele of CETP and the risk of CAD and
T2DM independent of HDL-C level [18]. Endothelial
NOS gene through coding endothelial NOS enzyme has
a role in maintaining normal endothelial function. Endo-
thelial NOS through synthesis of NO affects the relax-
ation of vascular smooth muscle, inhibition of adhesion
of platelets and leukocytes to the endothelium, reduction
of vascular smooth muscle cell migration and prolifera-
tion, and limitation of the oxidation of LDL-C [27,28].
There are several reports indicating an association be-
tween the NOS3 G894T polymorphism and the risk of
CAD [13,14]. However, some studies demonstrated the
lack of association between this polymorphism and the
risk of CAD [15,17,29]. Our recent work indicated that
the risk of CAD is elevated in the presence of NOS3 T
allele [19]. In the present work, we examined the influ-
ence of concomitant presence of NOS3 T and CETP B1
alleles on the risk of CAD and T2DM. We noticed thatthe risk of CAD augments in the presence of both alleles
in total CAD and in CAD patients with and without
T2DM to the level of 18.1-, 13.5-, and 27.1-fold, respect-
ively. Also, the combined presence of both alleles
increased the risk of T2DM by 12-fold. Our study
demonstrated that the presence of variations in more
than one gene play an important role in the susceptibil-
ity to CAD and T2DM.
The presence of hypercholesterolemia and oxidized
LDL-C downregulates NOS expression and rapid deg-
radation of NO. The exact mechanism of influence of
CETP variants and its interaction with NOS3 G894T
polymorphism on the risk of CAD and T2DM is unclear.
However, it has been suggested that contribution of
CETP to the formation of small dense LDL-C particles
and impairment of NO synthesis in the presence of
NOS3 G894T variants that are enhanced in hypercholes-
terolemia might lead to endothelial dysfunction and ath-
erosclerosis [30].
Briefly, our study indicated that the B1 allele of CETP
TaqIB polymorphism in combination with NOS3 T allele
augments the risk of CAD and T2DM in our population.
The results of the present study emphasize the role of
gene-gene interaction in the pathogenesis of complex
disorders such as CAD and T2DM that need to be con-
firmed in further studies from other populations.
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